Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
Drew R Oostra,1 Erin R Macrae21Division of Hematology, Oncology, and Transplant. University of Minnesota, Minneapolis, MN, USA; 2Division of Medical Oncology, The James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA Abstract: Trastuzumab is a monoclonal a...
Guardado en:
Autores principales: | Oostra DR, Macrae ER |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/504b23688d244ef187efc8edad690aab |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
por: Sawaki M
Publicado: (2014) -
Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
por: Laura M. Spring, et al.
Publicado: (2021) -
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Jamunarani Veeraraghavan, et al.
Publicado: (2021) -
Fibroblast growth factor receptor facilitates recurrence of minimal residual disease following trastuzumab emtansine therapy
por: Saeed S. Akhand, et al.
Publicado: (2021) -
Role of pertuzumab in the treatment of HER2-positive breast cancer
por: Hubalek M, et al.
Publicado: (2012)